Few studies have reported the application of RT plus EGFR TKIs in older patients with esophageal cancer.26,27 The combination of gefitinib plus RT for elderly patients was reported by Xu and colleagues.26 Their results showed a median OS of 14.0 months, with 5 of 20 patients experiencing severe toxic effects.26 In a pilot study18 evaluating the efficacy of concurrent erlotinib and RT for chemoradiotherapy-intolerant patients with ESCC, the median OS was 21.1 months, which is similar to our experimental group. Here, EGFR is linked to esophageal cancer.